Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. more
Time Frame | OKYO | Sector | S&P500 |
---|---|---|---|
1-Week Return | 1.92% | -2.27% | -0.57% |
1-Month Return | -3.64% | -3.96% | 1.21% |
3-Month Return | 2.91% | -9.7% | 7.57% |
6-Month Return | -22.06% | -3.37% | 11.45% |
1-Year Return | -35.76% | 3.71% | 28.48% |
3-Year Return | -70.72% | 3.8% | 29.52% |
Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
Cost of Revenue | 5.97K | 13.09K | 2.42K | 3.80K | 7.51K | [{"date":"2020-03-31","value":45.63,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":18.52,"profit":true},{"date":"2023-03-31","value":29.02,"profit":true},{"date":"2024-03-31","value":57.36,"profit":true}] |
Gross Profit | (5.97K) | (13.09K) | (2.42K) | (3.80K) | (7.51K) | [{"date":"2020-03-31","value":-597108,"profit":false},{"date":"2021-03-31","value":-1308600,"profit":false},{"date":"2022-03-31","value":-242301,"profit":false},{"date":"2023-03-31","value":-379700,"profit":false},{"date":"2024-03-31","value":-750616,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2020-03-31","value":null,"profit":false},{"date":"2021-03-31","value":null,"profit":false},{"date":"2022-03-31","value":null,"profit":false},{"date":"2023-03-31","value":null,"profit":false},{"date":"2024-03-31","value":null,"profit":false}] |
Operating Expenses | 1.51M | 3.37M | 6.22M | 13.19M | 8.24K | [{"date":"2020-03-31","value":11.47,"profit":true},{"date":"2021-03-31","value":25.53,"profit":true},{"date":"2022-03-31","value":47.15,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":0.06,"profit":true}] |
Operating Income | (1.52M) | (4.13M) | (6.22M) | (13.19M) | (15.75K) | [{"date":"2020-03-31","value":-151885000,"profit":false},{"date":"2021-03-31","value":-413334983,"profit":false},{"date":"2022-03-31","value":-621756600,"profit":false},{"date":"2023-03-31","value":-1318720000,"profit":false},{"date":"2024-03-31","value":-1574973,"profit":false}] |
Total Non-Operating Income/Expense | (95.73K) | 753.99K | 13.58K | (193.37K) | (1.05M) | [{"date":"2020-03-31","value":-12.7,"profit":false},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":1.8,"profit":true},{"date":"2023-03-31","value":-25.65,"profit":false},{"date":"2024-03-31","value":-139.84,"profit":false}] |
Pre-Tax Income | (1.62M) | (3.38M) | (6.22M) | (13.28M) | (16.80K) | [{"date":"2020-03-31","value":-161834400,"profit":false},{"date":"2021-03-31","value":-337850100,"profit":false},{"date":"2022-03-31","value":-621756600,"profit":false},{"date":"2023-03-31","value":-1328388700,"profit":false},{"date":"2024-03-31","value":-1680305,"profit":false}] |
Income Taxes | (76.19K) | (24.99K) | (786.52K) | (12.20K) | 22.42 | [{"date":"2020-03-31","value":-339848.35,"profit":false},{"date":"2021-03-31","value":-111480.82,"profit":false},{"date":"2022-03-31","value":-3508122.21,"profit":false},{"date":"2023-03-31","value":-54424.62,"profit":false},{"date":"2024-03-31","value":100,"profit":true}] |
Income After Taxes | (1.54M) | (3.35M) | (5.43M) | (13.27M) | (16.83K) | [{"date":"2020-03-31","value":-154215000,"profit":false},{"date":"2021-03-31","value":-335350700,"profit":false},{"date":"2022-03-31","value":-543104500,"profit":false},{"date":"2023-03-31","value":-1327168500,"profit":false},{"date":"2024-03-31","value":-1682547,"profit":false}] |
Income From Continuous Operations | (1.21M) | (3.00M) | (5.43M) | (13.27M) | (16.83M) | [{"date":"2020-03-31","value":-121438400,"profit":false},{"date":"2021-03-31","value":-299742900,"profit":false},{"date":"2022-03-31","value":-543104500,"profit":false},{"date":"2023-03-31","value":-1327168500,"profit":false},{"date":"2024-03-31","value":-1682546100,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
Net Income | (1.54M) | (3.35M) | (5.43M) | (13.27M) | (16.83K) | [{"date":"2020-03-31","value":-154214900,"profit":false},{"date":"2021-03-31","value":-335350700,"profit":false},{"date":"2022-03-31","value":-543104500,"profit":false},{"date":"2023-03-31","value":-1327168500,"profit":false},{"date":"2024-03-31","value":-1682546,"profit":false}] |
EPS (Diluted) | - | - | - | - | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
OKYO | |
---|---|
Cash Ratio | 0.56 |
Current Ratio | 0.72 |
Quick Ratio | 0.69 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
OKYO | |
---|---|
ROA (LTM) | -291.87% |
ROE (LTM) | -2968.51% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
OKYO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.39 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.39 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
OKYO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 14.11 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
OKYO Pharma Ltd ADR (OKYO) share price today is $1.06
Yes, Indians can buy shares of OKYO Pharma Ltd ADR (OKYO) on Vested. To buy OKYO Pharma Ltd ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OKYO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of OKYO Pharma Ltd ADR (OKYO) via the Vested app. You can start investing in OKYO Pharma Ltd ADR (OKYO) with a minimum investment of $1.
You can invest in shares of OKYO Pharma Ltd ADR (OKYO) via Vested in three simple steps:
The 52-week high price of OKYO Pharma Ltd ADR (OKYO) is $2.12. The 52-week low price of OKYO Pharma Ltd ADR (OKYO) is $0.81.
The price-to-earnings (P/E) ratio of OKYO Pharma Ltd ADR (OKYO) is
The price-to-book (P/B) ratio of OKYO Pharma Ltd ADR (OKYO) is 14.11
The dividend yield of OKYO Pharma Ltd ADR (OKYO) is 0.00%
The market capitalization of OKYO Pharma Ltd ADR (OKYO) is $36.54M
The stock symbol (or ticker) of OKYO Pharma Ltd ADR is OKYO